Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 7;16(4):575-587.
doi: 10.2215/CJN.12940820. Epub 2021 Mar 29.

Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial

Piero Ruggenenti  1   2 , Manuel Alfredo Podestà  1   2 , Matias Trillini  1 , Annalisa Perna  1 , Tobia Peracchi  1 , Nadia Rubis  1 , Davide Villa  1 , Davide Martinetti  1 , Monica Cortinovis  1 , Patrizia Ondei  2 , Carmela Giuseppina Condemi  2 , Carlo Maria Guastoni  3 , Agnese Meterangelis  4 , Antonio Granata  5 , Emanuele Mambelli  6 , Sonia Pasquali  7 , Simonetta Genovesi  8   9 , Federico Pieruzzi  8   9 , Silvio Volmer Bertoli  10 , Goffredo Del Rosso  11 , Maurizio Garozzo  12 , Angelo Rigotti  13 , Claudio Pozzi  14 , Salvatore David  15 , Giuseppe Daidone  16 , Giulio Mingardi  17 , Giovanni Mosconi  18 , Andrea Galfré  19 , Giorgio Romei Longhena  20 , Alfonso Pacitti  21 , Antonello Pani  22 , Jorge Hidalgo Godoy  1   23 , Hans-Joachim Anders  24 , Giuseppe Remuzzi  1 ; ARCADIA Study Organization
Collaborators, Affiliations
Clinical Trial

Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial

Piero Ruggenenti et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis.

Design, setting, participants, & measurements: In this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruited patients on maintenance hemodialysis with hypertension and/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25-10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to the maximally tolerated dose to achieve predefined target BP values. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the single components of the primary end point, new-onset or recurrence of atrial fibrillation, hospitalizations for symptomatic fluid overload, thrombosis or stenosis of the arteriovenous fistula, and changes in cardiac mass index. All outcomes were evaluated up to 42 months after randomization.

Results: At comparable BP control, 23 participants on ramipril (16%) and 24 on non-RAS inhibitor therapy (19%) reached the primary composite end point (hazard ratio, 0.93; 95% confidence interval, 0.52 to 1.64; P=0.80). Ramipril reduced cardiac mass index at 1 year of follow-up (between-group difference in change from baseline: -16.3 g/m2; 95% confidence interval, -29.4 to -3.1), but did not significantly affect the other secondary outcomes. Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinal malignancies on ramipril (four were fatal), compared with none in controls.

Conclusions: Ramipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis.

Clinical trial registry name and registration number: ARCADIA, NCT00985322 and European Union Drug Regulating Authorities Clinical Trials Database number 2008-003529-17.

Keywords: ACE inhibitors; Ramipril; cardiovascular events; hemodialysis; renin angiotensin system.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Study flow diagram. CV, cardiovascular.
Figure 2.
Figure 2.
Cumulative incidence of the primary composite outcome. Kaplan–Meier survival curves showing the risk of progression to the primary composite end point of cardiovascular death, acute myocardial infarction, or stroke in the ramipril group and non-RAS inhibitor group. Hazard ratios (crude and adjusted for age, sex, previous cardiovascular events or RAS inhibitor therapy, and presence of diabetes and left ventricular hypertrophy at inclusion) are reported in the figure. Only one event from the composite end point per participant, whichever occurred first, was included in the analysis. The number of participants at risk is shown in the bottom table. Blue line indicates the ramipril group; red line indicates the non-RAS inhibitor group. HR, hazard ratio; RAS, renin-angiotensin system.
Figure 3.
Figure 3.
Risk of progression to the single components of the primary composite end point, according to treatment arm. Kaplan–Meier survival curves showing the risk of the first occurrence of either (A) cardiovascular death, (B) nonfatal acute myocardial infarction, or (C) nonfatal stroke, considered as single end points in the ramipril group and non-RAS inhibition group. Hazard ratios (crude and adjusted for age, sex, previous cardiovascular events or RAS inhibitor therapy, and presence of diabetes and left ventricular hypertrophy at inclusion) are reported in the three panels. The number of participants at risk is shown in the bottom table. Blue line indicates the ramipril group; red line indicates the non-RAS inhibitor group.
Figure 4.
Figure 4.
Pre- and postdialysis systolic and diastolic BP over time (A and B), cardiac mass index at baseline and at 1 and 2 years after randomization (C), and serum potassium levels over time (D) in the two treatment groups. All data are expressed as mean±SEM. Blue indicates ramipril and red indicates non-RAS inhibitor therapy. *P<0.05 versus baseline; P values for between-groups comparisons are reported in the figure.
See this image and copyright information in PMC

Comment in

References

    1. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, Bhave N, Dietrich X, Ding Z, Eggers PW, Gaipov A, Gillen D, Gipson D, Gu H, Guro P, Haggerty D, Han Y, He K, Herman W, Heung M, Hirth RA, Hsiung JT, Hutton D, Inoue A, Jacobsen SJ, Jin Y, Kalantar-Zadeh K, Kapke A, Kleine CE, Kovesdy CP, Krueter W, Kurtz V, Li Y, Liu S, Marroquin MV, McCullough K, Molnar MZ, Modi Z, Montez-Rath M, Moradi H, Morgenstern H, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O’Hare AM, Obi Y, Park C, Pearson J, Pisoni R, Potukuchi PK, Repeck K, Rhee CM, Schaubel DE, Schrager J, Selewski DT, Shamraj R, Shaw SF, Shi JM, Shieu M, Sim JJ, Soohoo M, Steffick D, Streja E, Sumida K, Kurella Tamura M, Tilea A, Turf M, Wang D, Weng W, Woodside KJ, Wyncott A, Xiang J, Xin X, Yin M, You AS, Zhang X, Zhou H, Shahinian V: US Renal Data System 2018 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 73[Suppl 1]: A7–A8, 2019 - PMC - PubMed
    1. Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70: 1318–1324, 2006 - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004 - PubMed
    1. Jungers P, Nguyen Khoa T, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, Man NK: Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: A multicentric study in the Ile de France district. Nephrol Dial Transplant 14: 898–902, 1999 - PubMed
    1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9: 1136–1142, 1994 - PubMed

Publication types

Substances

Associated data